Alex Brill recently joined Garrett Ballengee, founding executive director of the Cardinal Institute for West Virginia Policy, on their podcast “Forgotten America.” In this fascinating interview, Brill discusses the economic impacts of the opioid crisis in America, noting that the epidemic is no longer just an Appalachian problem.
“That’s an impossible bar to clear, writes Alex Brill, an economist with Matrix Global Advisors and a fellow at the American Enterprise Institute, in a new report sponsored by the PBM lobby Pharmaceutical Care Management Association.”
Matrix Global Advisors (MGA) today released a new report, “Negative Economic Impact of Restricting Drug Rebates in Medicare Part D,” by MGA founder and CEO Alex Brill. The report looks at a July 2020 Executive Order on prescription drug rebates that invokes a proposed regulatory change President Trump withdrew a year earlier.
As the COVID-19 pandemic has swept across our country and claimed more than 100,000 lives in a few short months, the opioid epidemic, which dates back to at least the early 2000s, has received less attention. But the toll of the opioid crisis in the United States remains enormous by any measure.
“Brand-name medicines’ market exclusivity periods have climbed an average of 2.2 years since the mid-1990s, steadily delaying the market arrival of generic rivals. Reversing that trend alone could save the U.S. health care system roughly $31.7 billion, according to a Matrix report commissioned by the Coalition for Affordable Prescription Drugs, a group of insurers, pharmacy benefit managers and large employers.”
